Amylyx Pharmaceuticals, Inc. (AMLX) — Institutional Holders, Q2 2026 (page 3)
207 institutional investment managers reported a AMLX position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $2.1B. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 201 to 207. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
AMLX 13F holders ranked 201–207 of 207
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 201 | SALEM INVESTMENT COUNSELORS#201 · 55 sh | 55 | $988.00 | — | 0.0% |
| 202 | Caitong International Asset Management , Ltd#202 · 28 sh | 28 | $503.00 | <0.01% | -22.2% |
| 203 | Allworth Financial#203 · 26 sh | 26 | $467.00 | 0.00% | -35.0% |
| 204 | Essential Partners#204 · 15 sh | 15 | $269.00 | — | 0.0% |
| 205 | Global Retirement Partners#205 · 14 sh | 14 | $251.00 | 0.00% | — |
| 206 | SBI Securities , Ltd.#206 · 1 sh | 1 | $18.00 | — | 0.0% |
| 207 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#207 · 79,872 sh | 79,872 | — | — | +22.9% |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.